Condition: Radiotherapy · PD-1 Inhibitor · Capecitabine · Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma.
This description comes directly from the study's public registry record.
Zhigang MD Liu, PhD · 2528888 · zhigangliu1983@hotmail.com
Zhigang MD Liu, PhD · 2528888 · liuzhg9@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Fifth Affilliated Hospital of Sun Yat-sen University | Zhuhai, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05290194